GlassScriptPhysician profile
Charles Gennaula
NPI 1013914746
$7,963.06
in general payments reported to CMS, 2019-2025
30 companies · $206 in 2025
The $206 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,475 · 2020: $229 · 2021: $1,589 · 2022: $1,458 · 2023: $648 · 2024: $359 · 2025: $206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,013 · Consulting Fee: $150 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,012.66 |
| Consulting Fee | $150.00 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $3,259.83 | 2019-2022 | |
| Biogen, INC. | $1,706.29 | 2020-2023 | Tysabri, Vumerity |
| Genentech USA, INC. | $917.02 | 2022-2023 | Ocrevus |
| Abbvie INC. | $669.96 | 2021-2025 | |
| Lilly USA, LLC | $339.73 | 2019-2025 | Emgality, Reyvow, Amyvid |
| Pfizer INC. | $136.43 | 2025 | |
| Ucb, INC. | $108.42 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $90.95 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $86.99 | 2022-2024 | Ultomiris |
| Eisai INC. | $71.69 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $66.35 | 2022 | |
| Acadia Pharmaceuticals INC | $63.33 | 2023-2024 | Nuplazid |
| Averitas Pharma INC. | $44.86 | 2023 | Qutenza |
| Neurelis, INC. | $34.97 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $34.22 | 2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $31.33 | 2022 | |
| Upsher-Smith Laboratories LLC | $29.47 | 2020 | |
| Collegium Pharmaceutical, INC. | $28.06 | 2022 | |
| Tanabe Pharma America, INC. | $26.63 | 2020 | |
| Sk Life Science, INC. | $25.68 | 2023 | |
| Allergan, INC. | $24.83 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $24.66 | 2021 | |
| Emd Serono, INC. | $23.46 | 2019 | |
| Tg Therapeutics, INC. | $21.18 | 2024 | |
| Livanova USA, INC. | $19.14 | 2019 | |
| Mdd US Operations, LLC | $18.59 | 2021 | |
| Adamas Pharmaceuticals, INC. | $18.41 | 2020 | |
| Medtronic Vascular, INC. | $16.20 | 2019 | |
| Neurocrine Biosciences, INC. | $12.41 | 2020 | |
| Celgene Corporation | $11.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Gennaula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.